Drug intelligence / Profile preview

GSB D300

Development stage: Unknown
Lead developer: Greenstone Biosciences

Overview

GSB D300 is a preclinical drug candidate developed by GreenStone Biosciences for inflammatory indications. The compound is currently in the IND-enabling stage, which means it is undergoing studies required before entering human clinical trials. Specific details about its mechanism of action, molecular target, or chemical class have not been publicly disclosed as of June 2025. GreenStone Biosciences utilizes advanced AI-driven platforms for drug discovery and ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction to accelerate the development of novel therapeutics[1][2].

Beyond the preview

Go deeper on GSB D300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSB D300.

Explore the full profile